Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Novabay Pharmaceuticals (NBY)

Novabay Pharmaceuticals (NBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,971
  • Shares Outstanding, K 36,061
  • Annual Sales, $ 14,730 K
  • Annual Income, $ -9,640 K
  • 60-Month Beta 1.97
  • Price/Sales 0.21
  • Price/Cash Flow N/A
  • Price/Book 0.69
Trade NBY with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.44
  • Most Recent Earnings $-0.95 on 03/26/24
  • Latest Earnings Date 05/09/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.85
  • Growth Rate Est. (year over year) +117,629.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0650 +11.54%
on 04/22/24
0.1500 -51.67%
on 03/26/24
-0.0637 (-46.77%)
since 03/22/24
3-Month
0.0650 +11.54%
on 04/22/24
0.1990 -63.57%
on 01/29/24
-0.0835 (-53.53%)
since 01/22/24
52-Week
0.0650 +11.54%
on 04/22/24
1.5200 -95.23%
on 04/24/23
-1.4875 (-95.35%)
since 04/21/23

Most Recent Stories

More News
PhaseOne Health Collaborates with Nonprofit Humanitarian Organization to Supply NovaBay Pharmaceuticals’ Phase One® Skin and Wound Cleanser to Ukraine

PhaseOne Health announces it has provided PhaseOne Skin and Wound Cleanser (PhaseOne) as part of a $3 million donation of medical supplies to Ukraine in partnership with the nonprofit HelpingUkraine.us...

NBY : 0.0725 (-12.01%)
NovaBay Pharmaceuticals to Hold First Quarter 2023 Conference Call on May 11, 2023

NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three months ended March 31, 2023 after market close on Thursday, May 11, 2023 and will hold...

NBY : 0.0725 (-12.01%)
NovaBay Pharmaceuticals Fulfills $1 Million Order for NeutroPhase® Skin and Wound Cleanser for China Pioneer Pharma Holdings

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces that China Pioneer Pharma Holdings, Limited (HK Stock Code:1345), a leading Chinese importer and marketer of branded pharmaceuticals and medical...

NBY : 0.0725 (-12.01%)
NovaBay Pharmaceuticals Announces $3.0 Million Convertible Note Financing

NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announced today that it has entered into a securities purchase agreement with institutional accredited investors...

NBY : 0.0725 (-12.01%)
NovaBay Pharmaceuticals Launches DERMAdoctor’s New Comfort + Joy Psoriasis Therapeutic Moisturizing Cream on the QVC® Network

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Chief Product Officer and board-certified...

NBY : 0.0725 (-12.01%)
NovaBay Pharmaceuticals Reports 2022 Fourth Quarter and Full Year Financial Results

NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) reports financial results for the three and 12 months ended December 31, 2022 and provides a business update. Financial results for 2022 include...

NBY : 0.0725 (-12.01%)
NovaBay Pharmaceuticals to Hold 2022 Fourth Quarter and Full Year Conference Call on March 30, 2023

NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December 31, 2022 after market close on Thursday, March 30, 2023...

NBY : 0.0725 (-12.01%)
Eyeganics Organic Tears, the Only USDA-Certified Organic Lubricant Eye Drop, Now Available through NovaBay Pharmaceuticals’ Avenova.com and Physician-Dispensed Channel

NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) announces a partnership with Eyeganics to sell OTC Organic Tears (0.2% organic glycerin) on Avenova.com and through Avenova’s physician-dispensed...

NBY : 0.0725 (-12.01%)
NovaBay Pharmaceuticals Launches Avenova® Eye Health Support, a New Antioxidant-Rich Oral Supplement to Comfort Dry Eyes and Promote Overall Eye Health

NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) announces the launch of OTC Avenova Eye Health Support oral supplement featuring a combination of MaquiBright ® , a nutrient-rich, antioxidant-dense...

NBY : 0.0725 (-12.01%)
NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctor’s Eczema Treatment on Two QVC® Shows on February 7

NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) announces that Chief Product Officer Audrey Kunin, MD will be a live on-air guest on two QVC network shows on February 7, 2023. Dr. Kunin will be...

NBY : 0.0725 (-12.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds,...

See More

Key Turning Points

3rd Resistance Point 0.1050
2nd Resistance Point 0.0955
1st Resistance Point 0.0840
Last Price 0.0725
1st Support Level 0.0630
2nd Support Level 0.0535
3rd Support Level 0.0420

See More

52-Week High 1.5200
Fibonacci 61.8% 0.9642
Fibonacci 50% 0.7925
Fibonacci 38.2% 0.6208
Last Price 0.0725
52-Week Low 0.0650

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar